Bayer Corporation

Bayer Aktiengesellschaft

Bayer Healthcare LLC

Bayer Intellectual Property Gmbh

Cynthia J Galloway

Hans-Jürgen Henzler

George A Baumbach

Michael H Coan

Klaus Kaiser

Rolf Treckmann

Joerg Kauling

David J Hammond

Hans-Juergen Henzler

Vivian W Lee

John M Lang

Kathryn Remington

Kathryn M Remington

A method of inactivating microorganisms such as viruses within a fluid such as a biological fluid is disclosed. The method includes the steps of providing a UV reactor, which may take the form of an elongated generally annular reaction chamber surrounding at least one elongated UV lamp, moving the fluid within the reaction chamber in a primary flow directed along the length of the UV lamp, and inducing a circulating secondary flow within the fluid with the secondary flow being superimposed on the primary flow. As the fluid moves through the reaction chamber in the primary flow, it is circulated repeatedly toward and away from the UV lamp in the circulating secondary flow to provide uniform and controllable exposure of the entire volume of fluid to ultraviolet radiation. Microorganisms such as viruses are thus inactivated while desirable components in the fluid, such as proteins, are preserved without the use of a free radical scavenger.

Method of inactivating microorganisms in a fluid using ultraviolet radiation

A process for viral inactivation of a solution containing a biologically active protein, wherein the process comprises the steps of 1) contacting the solution with an immobilized ligand under conditions which allow protein to bind to the ligand, 2) subjecting the bound protein to a viral inactivation method under conditions which would result in substantial denaturation of the protein if it were not bound to the ligand, and 3) recovering the protein by washing the immobilized protein under conditions which favor the release of the protein into the solution under conditions in which the recovered protein retains its biological activity.

Selective stabilization of protein during viral inactivation

A method of controlling the amount of a biologically active substance binding to a cell surface having both receptors to the substance and receptors for the Fc domain of an antibody that can complex with the substance or other antibodies that can complex with the substance. By exploiting the generally more numerous Fc receptor sites, substance binding can be increased and/or controlled. Method contemplates controlling amounts of substances such as cytokines, hormones, and growth factors that are associated with cells such as monocytes, macrophages, granulocytes, B cells, T cells, and platelets. Method is illustrated using conjugated antibodies to tissue necrosis factor (TNF) to increase the binding of TNF to monocytes.

Cell surface receptor complementation

Growing community of inventors

Garner, NC, United States of America

Cynthia J Galloway